Pay in 4 interest-free payments of $7.07 Learn more
Ships within 48 hours · Estimated delivery Sep 1 - Sep 6
reported IC/BPS patients had increased inflammatory urine markers, including vascular endothelial growth factor (VEGF) and CXCL10, than OAB patients 13
Weight Loss Up to ~21% reduction Sustained at 72 weeks Beats GLP-1 alone Glycemic Control Lower HbA1c Steadier blood sugar GIP boosts response Cardiometabolic Lower blood pressure Better lipid panel Trial signals on CV Appetite Control Quieter cravings Smaller portions Less food noise Lose more weight on your terms
Because booming consumer demand for GLP-1s was a primary reason for the shortages, it was a gold rush situation for compounders who made full use of regulatory gaps to build a large secondary market for their compounded GLP-1s by advertising the benefits without disclosing the risks
Expected results timeline Week 1-2 What to expect : Reduced pain (20-40%) Less inflammation Improved sleep quality Slight improvement in function What not to expect : Complete healing yet
